Results 111 to 120 of about 37,394 (238)

Amyloidosis presenting as bilateral transudative pleural effusions with normal cardiac investigations: a case report [PDF]

, 2009
A 66-year-old man with a diagnosis of monoclonal gammopathy of unknown significance was referred for investigation of bilateral transudative pleural effusions by the cardiology team.
James H Briggs, William G Singleton, Margaret M Burke, Lorraine A Hart, Robert J Parker   +4 more
core   +1 more source

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.

Biology of Blood and Marrow Transplantation, 2019
In immunoglobulin light-chain (AL) amyloidosis, the depth of hematologic response to treatment is associated with improved survival and organ responses. We conducted a clinical trial using bortezomib in induction and in conditioning with melphalan before
V. K. Gupta, D. Brauneis, A. Shelton, K. Quillen, S. Sarosiek, J. Sloan, V. Sanchorawala   +6 more
semanticscholar   +1 more source

Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

European Journal of Haematology, Volume 116, Issue 6, Page 889-906, June 2026.
ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre‐cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely ...
Stephen James Quinn, Chris Cardwell, Lesley Ann Anderson, Charlene McShane   +3 more
wiley   +1 more source

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Blood, 2018
TO THE EDITOR: Systemic amyloid light-chain amyloidosis (AL) is characterized by deposition of misfolded immunoglobulin light chains within organs. AL with an immunoglobulin M (IgM) monoclonal protein (IgM-AL) accounts for 5% to 7% of AL and exhibits ...
R. Manwani, S. Sachchithanantham, S. Mahmood, Darren Foard, F. Sharpley, T. Rezk, T. Lane, C. Quarta, M. Fontana, H. Lachmann, J. Gillmore, C. Whelan, P. Hawkins, A. Wechalekar   +13 more
semanticscholar   +1 more source

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches

Brain and Behavior, Volume 16, Issue 5, May 2026.
Chronic inflammatory demyelinating polyneuropathy is an autoimmune disorder causing demyelination, leading to distal weakness, sensory loss, and autonomic dysfunction. Immune activation triggers macrophage‐mediated myelin damage and conduction failure.
Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam   +11 more
wiley   +1 more source

Cutaneous light chain amyloidosis and erythema elevatum diutinum as the presenting features of IgA monoclonal gammopathy: a rare case report and comprehensive literature review

Annals of Hematology
Monoclonal gammopathy (MG) associated with dermatological disorders, which is classified as monoclonal gammopathy of clinical significance (MGCS), represents a well-established complication.
Bing Han, Junfeng Zhou, Hesong Liu, Shanshan Li, Hong Wang   +4 more
doaj   +1 more source

Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds [PDF]

, 2018
PURPOSE: 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart.
Burniston, M, Hawkins, PN, Manwani, R, McCool, D, Page, J, Ross, JC, Skillen, A, Wagner, T, Wechalekar, AD   +8 more
core   +1 more source

Detection of vascular amyloid deposits in a bone marrow aspirate

British Journal of Haematology, EarlyView.
Konstantinos Liapis, Georgios Kanellis, Georgios Vrachiolias, Evangelia Charitaki   +3 more
wiley   +1 more source

Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation

Cancer Medicine, Volume 15, Issue 5, May 2026.
1. Some patients experience MRD progression (MRD‐P) before clinical or biochemical progression (PD), highlighting the value of MRD monitoring for the early detection of relapse. 2. Early intervention upon MRD progression in multiple myeloma patients was associated with improved survival outcomes and higher rates of MRD re‐negativity.
Xiaozhe Li, Meilan Chen, Lifen Kuang, Junru Liu, Beihui Huang, Juan Li   +5 more
wiley   +1 more source

Monoclonal gammopathy with systemic amylodosis: an evaluation of diagnostic elements [PDF]

, 2011
Monoclonal gammopathies result from an overproduction of a single abnormal clone of plasma cell or B lymphocyte that produce an immunologically homogenous immunoglobulin (Ig) commonly referred to as paraprotein or monoclonal (M) protein.
Chellappah Thambiah, Subashini, George, Elizabeth, Umar, Nor Aini   +2 more
core